- In children with advanced anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMTs), crizotinib (Xalkori) is safe and effective.
Why this matters
- Advanced ALCL and IMTs have a poor prognosis.
- In this phase 2 Children's Oncology Group trial, safety and efficacy of crizotinib were studied at different doses in 26 patients with relapsed/refractory ALK-positive ALCL and 14 patients with metastatic or inoperable ALK-positive IMT.
- Response was defined by a positive response for a minimum of 2 consecutive imaging studies at least 4 wk apart.
- Funding: National Cancer Institute, Pfizer, and Cookies for Kids Cancer Foundation.
- 83% of patients with ALCL who received a dose of 165 mg/m2 responded and 90% of patients who received a dose of 280 mg/m2 responded.
- Complete response was seen in 83% of the 165 mg/m2 group and 80% of the 280 mg/m2 group of patients with ALCL.
- 86% of patients with IMT responded (doses of 100, 165, and 280 mg/m2).
- A complete response was seen in 36% of patients with IMT.
- The most frequent adverse event was a lowering of neutrophil count in 33%-70% patients of the ALCL group and 43% patients of IMT group.
- Small sample sizes.